UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
September 26, 2009
Date of Report (Date of earliest event reported)
ABBOTT LABORATORIES
(Exact name of registrant as specified in its charter)
|
Illinois |
|
1-2189 |
|
36-0698440 |
|
(State or other jurisdiction |
|
(Commission File Number) |
|
(IRS Employer |
|
of incorporation) |
|
|
|
Identification No.) |
100 Abbott Park Road
Abbott Park, Illinois 60064-6400
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (847) 937-6100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Material Definitive Agreement
On September 28, 2009, Abbott announced it entered into a definitive agreement with the Solvay Group for Abbott to acquire Solvay’s pharmaceutical (including vaccine) and diagnostics businesses. The agreement is subject to customary closing conditions and regulatory approvals. A copy of the press release announcing the agreement is attached as Exhibit 99.1.
|
Exhibit No. |
|
Exhibit |
|
|
|
|
|
99.1 |
|
Press Release, dated September 28, 2009. |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
ABBOTT LABORATORIES |
|
|
|
|
|
|
|
|
|
|
Date: September 28, 2009 |
By: |
/s/ Thomas C. Freyman |
|
|
|
Thomas C. Freyman |
|
|
|
Executive Vice President, Finance |
|
|
|
and Chief Financial Officer |
3
EXHIBIT INDEX
|
Exhibit No. |
|
Exhibit |
|
|
|
|
|
99.1 |
|
Press Release, dated September 28, 2009. |
4